INDP
Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.22
+5.17%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.8x
Market Cap
$162.56M
MomentumView details →
1D Return
+5.17%
YTD Return
−59.11%
RSI (14)
42.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.8x
Market Cap
$162.56M
RSI (14)
42.4
MomentumView details →
1D Return
+5.17%
YTD Return
−59.11%
SummaryUpdated Jun 1, 2026
Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a pre-clinical biotechnology company founded in 2021 and headquartered in New York, New York. The company was formerly known as Intec Parent, Inc. before changing its name to Indaptus Therapeutics in August 2021. As a development-stage biopharmaceutical company, Indaptus focuses on creating innovative immunotherapy treatments for cancer and viral infections, with its lead candidate currently in Phase I clinical trials.
Similar companies
Latest newsMore news →
Tim Ruan resigned as Director of the Board of Directors of Indaptus Therapeutics, Inc., effective September 2, 2026.21m agoIndaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to issue and sell common stock with an aggregate maximum offering price of up to $100,000,000.3d ago